Clinical vs Genomic Risks in Breast Cancer in 2019: Breast Pathologist's Appellate Review of the Controversial Results From TAILORx Trial - PubMed

Clinical vs Genomic Risks in Breast Cancer in 2019: Breast Pathologist's Appellate Review of the Controversial Results From TAILORx Trial - PubMed

Clinical vs Genomic Risks in Breast Cancer in 2019: Breast Pathologist's Appellate Review of the Controversial Results From TAILORx Trial

Christina H Wei 1 2, Robert West 2, Daniel Schmolze 1, Sophia K Apple 1 3

Affiliations 

• PMID: 32077570
 
• DOI: 10.1111/tbj.13771

Similar articles

• A Pathologist's Perspective on Emerging Genomic Tests for Breast Cancer

  WF Symmans. Semin Oncol 34 (2 Suppl 3), S4-9. Apr 2007. PMID 17512433. - Review

  Emerging molecular tests for breast cancer indicate how future progress in diagnostic pathology might guide patient care. However, the challenge will be to bring the best …
• Clinicopathologic Analysis of 722 Breast Cancer Patients Who Met the Inclusion Criteria of the TAILORx Trial

  HY Xiang et al. Chin Med J (Engl) 132 (24), 2914-2919. 2019. PMID 31809316.

  In the absence of internationally recognized multigene testing methods, for patients with early hormone receptor-positive, HER2-negative breast cancer, clinicians can dev …
• Effect of Pathologist's Dedication on Lymph Node Detection Rate and Postoperative Survival in Colorectal Cancer

  LW Unger et al. Colorectal Dis 20 (7), O173-O180. Jul 2018. PMID 29706021.

  In our centre, the pathologist's dedication has an impact on lymph node detection rate but does not influence postoperative disease-specific survival.
• The Clinical Significance of Minimal Breast Cancer: A Pathologist's Viewpoint

  JA Wirman. Crit Rev Oncol Hematol 3 (1), 35-74. 1985. PMID 2990747. - Review

  We can draw the following conclusions about minimal breast cancer: The concept of minimal breast cancer as a stage of cancer that is 95% curable is a valid one, if minima …
• [Breast Cancer: The Pathologist's Viewpoint]

  CY Genton. Rev Med Suisse Romande 110 (4), 307-10. Apr 1990. PMID 2160119.